Press Releases
  • October, 23 2014  | Aduro presents updated interim results from Phase 1b clinical trial in mesothelioma at International Mesothelioma Interest Group Conference  READ IT HERE
  • October, 16 2014  | Aduro expands collaboration with Johnson & Johnson Innovation and Janssen for lung cancer immunotherapies  READ IT HERE
  • October, 15 2014  | Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference  READ IT HERE
  • October, 09 2014  | Aduro BioTech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., a featured speaker on action of vaccine adjuvants at Keystone Symposia  READ IT HERE
  • September, 22 2014  | Aduro BioTech named one of Fierce 15 leading biotech companies in 2014  READ IT HERE
  • July, 21 2014  | Aduro receives breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy  READ IT HERE
  • July, 17 2014  | Aduro names industry veteran and academic leader, Gerald Chan, DSc to its board of directors  READ IT HERE
  • June, 11 2014  | Aduro secures $55 million Series C financing  READ IT HERE
  • June, 02 2014  | Aduro announces ASCO presentation of promising results from Phase 1b clinical trial of its novel immunotherapy for the treatment of mesothelioma  READ IT HERE
  • May, 29 2014  | Aduro announces license agreement with Johnson & Johnson Innovation for novel immunotherapies for prostate cancer  READ IT HERE
  • May, 05 2014  | Aduro BioTech announces initiation of a clinical trial of its novel immunotherapy in patients with brain cancer at Providence Cancer Center  READ IT HERE
  • April, 09 2014  | Congratulations to Dr. Elizabeth Jaffee on selection to lead Stand Up To Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team  READ IT HERE
  • April, 08 2014  | Congratulations to Drs. Dung Le and Todd Crocenzi for award of 2014 Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant  READ IT HERE
  • February, 10 2014  | Aduro BioTech announces initiation of Phase 2b ECLIPSE trial to evaluate treatment of patients with pancreatic cancer with the company’s innovative immunotherapies  READ IT HERE
  • January, 14 2014  | Aduro announces Phase 2 clinical trial results demonstrating statistically significant survival benefit in pancreatic cancer patients treated with its novel immunotherapies  READ IT HERE
  • January, 14 2014  | Aduro’s Phase 2 trial of GVAX plus CRS-207 is one of five key studies highlighted by ASCO for the 2014 Gastrointestinal Cancers Symposium (please scroll to bottom of press release to open more information on promising vaccine combination)   READ IT HERE

  • Events
  • September, 10 2014  | Stephen Isaacs interviewed about Aduro's mesothelioma program  LISTEN TO IT HERE
  • May, 20 2014  | Aduro announces pancreatic cancer and mesothelioma abstracts to be presented at 2014 ASCO annual meeting  READ IT HERE
  • March, 07 2014  | Dirk Brockstedt presents at the 11th Annual International Symposium on Malignant Mesothelioma (first presentation on video, ends at 15:45)  WATCH IT HERE
  • February, 19 2014  | Chief Executive Officer, Stephen Isaacs presents at BIO CEO & Investor Conference (registration required to view video)  WATCH IT HERE
  • January, 30 2014  | Aduro announces presentations at the upcoming BIO CEO and Investor Conference and Leerink Global Healthcare Conference  READ IT HERE

  • Articles
  • October, 30 2014  | 5 Lifesaving Medical Breakthroughs (see #2)  READ IT HERE
  • February, 20 2014  | Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer  READ IT HERE
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use